Biogen, Alkermes get USFDA nod for multiple sclerosis drug Vumerity

The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous system and can lead to fatigue, pain, vision loss and impaired coordination and motor skills.

New Delhi: The U.S. Food and Drug Administration approved Biogen Inc and partner Alkermes Plc's oral drug to treat multiple sclerosis, the companies said on Wednesday.

The approval is good news for Biogen as its top-selling drug Tecfidera, also a multiple sclerosis treatment is facing patent challenges and increased competition from newer treatments such as Roche AG's Ocrevus.

The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous system and can lead to fatigue, pain, vision loss and impaired coordination and motor skills.

Biogen said it would make the drug available in the United States in the near future.

Read Also: Biogen in consultation with USFDA plans regulatory filing for AD drug Aducanumab

Earlier this month, Alkermes disclosed that the drug had received tentative approval. At the time, brokerage Wedbush estimated Vumerity to bring sales of about $800 million at its peak. Tecfidera brought Biogen sales of $4.27 billion last year.

Wednesday's approval was based on data comparing Vumerity and Tecfidera, the companies said in a statement.

Under the terms of a license agreement between the two companies, Biogen will pay Alkermes $150 million and royalties from the worldwide commercial sales of the drug.

Read Also: Biogen Alzheimer drug Aducanumab failure wipes USD 18 billion from market value